DrugPatentWatch Database Preview
GANZYK-RTU Drug Profile
» See Plans and Pricing
When do Ganzyk-rtu patents expire, and when can generic versions of Ganzyk-rtu launch?
Ganzyk-rtu is a drug marketed by Exela Pharma and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in GANZYK-RTU is ganciclovir. There are twenty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ganciclovir profile page.
US ANDA Litigation and Generic Entry Outlook for Ganzyk-rtu
Indicators of Generic Entry
Summary for GANZYK-RTU
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | GANZYK-RTU at DailyMed |
Pharmacology for GANZYK-RTU
| Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral |
| Mechanism of Action | DNA Polymerase Inhibitors |
US Patents and Regulatory Information for GANZYK-RTU
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | GANZYK-RTU | ganciclovir | SOLUTION;INTRAVENOUS | 209347-001 | Feb 17, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
